balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Chronic Kidney DiseaseHeart Failure and Impaired Kidney Function

Phase 2

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease

CompletedNCT06350123

AstraZenecaChronic Kidney Disease

Start: 2024-05-01End: 2025-05-09Updated: 2026-06-26

Phase 3

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

RecruitingNCT06307652

AstraZenecaHeart Failure and Impaired Kidney Function

Start: 2024-04-12End: 2027-04-16Target: 3850Updated: 2026-09-11

Related Papers

Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.

2025-11-082 citations

Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial.

2025-11-013 citations

#1585 Design and baseline characteristics of MIRO-CKD: a phase IIb, randomised, double-blind clinical trial to evaluate effects of balcinrenone in combination with dapagliflozin vs. dapagliflozin in patients with CKD

Nephrology Dialysis Transplantation2025-10-01

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure2025-05-193 citations

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology2025-02-172 citations